CLOs on the Move

MycoWorks

www.mycoworks.com

 
In 2013, co-founders Philip Ross and Sophia Wang formed MycoWorks, a San Francisco-based biomaterials company dedicated to bringing new mycelium-grown materials to the world. MycoWorks` patented Fine Mycelium™ technology, an advanced manufacturing platform and breakthrough in materials science, engineers mycelium during growth to form proprietary, interlocking cellular structures for unparalleled beauty, handfeel, strength and durability. The company`s flagship material- Reishi™ - is a new category of material for the world`s best luxury brands.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.mycoworks.com
  • 669 Grand View Avenue
    San Francisco, CA USA 94608
  • Phone: 510.479.0060

Executives

Name Title Contact Details
Craig Fleishman
General Counsel Profile

Similar Companies

Saneron CCEL Therapeutics

Saneron CCEL Therapeutics is a Tampa, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Immusoft

Immusoft Corporation (immusoft.com) is a pre-clinical gene therapy company based in Seattle, Wash. Its mission is to treat diseases using its breakthrough technology platform called Immune System Programming.

Iovance Biotherapeutics

Iovance Biotherapeutics is a biopharmaceutical startup based in San Carlos, California.

Icon Genetics

Icon Genetics is a Princeton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Capsida

We are a biotechnology company creating a new class of targeted gene therapies for debilitating and life-threatening genetic disorders in both central nervous system (CNS) and non-CNS indications. Current gene therapy approaches have shown dramatic efficacy in several rare diseases but are hindered by imprecise targeting. The inability to selectively transduce specific cells and tissues effectively drives administration of higher doses and resulting safety liabilities. We are addressing these concerns with our proprietary adeno-associated virus (AAV) engineering platform that generates capsids optimized to target specific tissues and cells in the disease organ while limiting transduction of tissues and cells not relevant to the target disease. Through our next-generation AAV platform combined with cargo development and state-of-the-art manufacturing, we are tackling monogenetic and sporadic CNS and non-CNS disorders that have previously been challenging to address.